Rgenta Therapeutics to Present at AACR Annual Meeting
Rgenta Therapeutics is poised to make an impactful presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in 2025. This clinical-stage biotechnology company specializes in developing innovative oral small molecules targeting RNA and RNA regulation. The spotlight will be on its lead program, RGT-61159, which has shown promising preclinical data.
Overview of RGT-61159
RGT-61159 is designed to specifically modify the splicing of the MYB transcription factor, ultimately leading to the inhibition of the oncogenic MYB protein. This inhibition is vital for inducing potential cell death in cancer cells that overexpress MYB. MYB has garnered attention as it regulates crucial processes such as cell proliferation and differentiation. The implications of MYB's aberrant expression are pertinent in various cancers, including acute myeloid leukemia and adenoid cystic carcinoma.
Presentation Details at AACR
The presentation of RGT-61159 is scheduled for April 30, 2025, between 9:00 AM and 12:00 PM CT. The session falls under the category of Chemistry and is focused on Targeted Protein Degradation. Attendees can look forward to interacting with the research team's findings on this cutting-edge therapy.
Clinical Insights and Trials
Rgenta is currently undertaking a multi-center, open-label Phase 1a/b clinical trial of RGT-61159. This study aims to assess the safety, tolerability, pharmacokinetics, and target engagement of the drug in patients suffering from advanced relapsed or refractory diseases such as acute myeloid leukemia or adenoid cystic carcinoma. This crucial trial represents a significant step towards understanding the clinical efficacy of RGT-61159, with hopes of delivering a robust therapeutic option for patients.
About Rgenta Therapeutics
As a pioneering biotechnology company, Rgenta is focused on developing a pipeline of RNA-targeting small molecule medicines. The company's unique approach leverages extensive genomics data to identify targetable RNA processing events, enabling the creation of small-molecule glues that modulate protein and RNA interactions. By focusing on historically undruggable targets, they are striving to unlock new therapeutic potentials, especially within oncology and neurological disorders.
Commitment to Innovation
Rgenta Therapeutics is dedicated to expanding its portfolio of innovative treatments through rigorous research and development efforts. Their commitment to science and patient care drives their mission to provide hope and improved outcomes for individuals battling significant health challenges. With groundbreaking programs like RGT-61159, Rgenta is at the forefront of transforming how we approach complex diseases.
Frequently Asked Questions
What is Rgenta Therapeutics known for?
Rgenta Therapeutics is known for developing oral small molecules targeting RNA to treat various cancers and neurological disorders.
When will RGT-61159 be presented?
The presentation of RGT-61159 will occur on April 30, 2025, during the AACR Annual Meeting.
What types of trials is RGT-61159 involved in?
RGT-61159 is undergoing a Phase 1a/b clinical trial assessing its safety and efficacy in patients with advanced relapsed or refractory cancers.
What is the significance of the MYB protein?
MYB protein plays a crucial role in cell proliferation and differentiation, and its dysregulation is implicated in various cancers.
How does Rgenta Therapeutics approach drug development?
Rgenta employs a unique platform that utilizes genomics data to identify RNA processing events, aiming to develop therapies for previously challenging diseases.
